The PD-1 inhibitor sasanlimab showed anti-tumor activity and manageable safety in combination with BCG induction and maintenance compared with standard of care in patients with BCG-naïve high-risk ...
Among patients with NMIBC, BCG treatment may be less effective for patients with a history of UTUC, suggesting they are at greater risk for progression. The efficacy of intravesical Bacillus ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s largest independent providers of ...
SPARKS, NV / ACCESSWIRE / September 20, 2022 / (OTC PINK:LUDG) Ludwig Enterprises, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to ...
Across a range of doses, 16 of 22 patients had a complete response to detalimogene voraplasmid (EG-70), including 15 at 3 months and 10 at 6 months. Additionally, seven of 10 patients treated with the ...
Anktiva boosted responses to BCG treatment without affecting quality of life, research showed. A novel “immune enhancer” improved outcomes and did not affect quality of life in patients with Bacillus ...
July 27, 2022 – A combination of two intravesical chemotherapy drugs – gemcitabine and docetaxel – yields high response rates with good tolerability in patients with high-risk non-muscle-invasive ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the final 60-month follow-up data from the Phase 3 study of ADSTILADRIN ® (nadofaragene firadenovec-vncg) were presented at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback